| Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. | |
| | |
MedLine Citation:
|
PMID: 18325306 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Risk stratification for primary prevention of sudden cardiac death (SCD) remains a major challenge in cardiology. The utility of T-wave alternans (TWA) as a marker of risk of life-threatening ventricular tachycardia and fibrillation is supported by two decades of basic and clinical research. Both frequency- and time-domain methods have been developed, validated, and made available in clinical practice. A principal application of TWA testing has been to improve assessment of patients with depressed left ventricular ejection fraction (EF; </= 40%) who are considered for implantable cardioverter-defibrillator (ICD) implantation for primary prevention of SCD. TWA has been most useful in identifying patients who are unlikely to benefit from ICD therapy. Although patients with low EF should remain an important focus, the absolute number of SCD events is far greater among post-myocardial infarction patients with relatively preserved EF, even though the incidence of SCD in this population is low. Recent studies suggest that TWA testing is predictive in this population as well. Absolute quantification of TWA rather than binary classification into "normal" or "abnormal" appears to be valuable in more finely stratifying the magnitude of arrhythmic risk. Longitudinal testing may be warranted in certain populations, although the optimum interval remains to be determined. Combining TWA with noninvasive markers of autonomic function, such as heart rate turbulence, may further increase predictive accuracy. Future development will likely expand the role of TWA testing with routine exercise and ambulatory electrocardiographic monitoring to screen lower-risk populations and to guide medical and device-based therapy. |
| | |
Authors:
|
Kapil Kumar; Kevin F Kwaku; Richard L Verrier |
Related Documents
:
|
17620506 - Prediction of mode of death in heart failure: the seattle heart failure model. 16996876 - Determinants of sudden cardiac death in patients with persistent atrial fibrillation in... 22661186 - Antiarrhythmic effect of prolonged morphine exposure is accompanied by altered myocardi... 6741836 - Risk factors for sudden death after acute myocardial infarction: two-year follow-up. 3021836 - Regulation of the right coronary circulation during a controlled behavioral stress in t... 6334436 - Transient st-segment depression as a marker of myocardial ischemia during daily life. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current treatment options in cardiovascular medicine Volume: 10 ISSN: 1092-8464 ISO Abbreviation: Curr Treat Options Cardiovasc Med Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-03-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815942 Medline TA: Curr Treat Options Cardiovasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: 39-48 Citation Subset: - |
Affiliation:
|
Richard L. Verrier, PhD Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Room 223, Boston, MA 02115, USA. rverrier@bidmc.harvard.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Management of the metabolic syndrome in cardiovascular disease.
Next Document: New strategies for cardiopulmonary resuscitation.